Get the Stockscreener App
24.12
3.34%
0.78
After Hours:
24.13
0.010
+0.04%
Enovis Corp stock is traded at $24.12, with a volume of 1.03M.
It is up +3.34% in the last 24 hours and up +6.54% over the past month.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
See More
Previous Close:
$23.34
Open:
$23.52
24h Volume:
1.03M
Relative Volume:
1.06
Market Cap:
$1.39B
Revenue:
$2.25B
Net Income/Loss:
$-1.18B
P/E Ratio:
-1.1656
EPS:
-20.6926
Net Cash Flow:
$19.92M
1W Performance:
+3.08%
1M Performance:
+6.54%
6M Performance:
-23.40%
1Y Performance:
-29.39%
1-Day Range:
$23.23
$24.70
1-Week Range:
$22.23
$24.70
52-Week Range:
$21.00
$37.85
Enovis Corp Stock (ENOV) Company Profile
Name
Enovis Corp
Sector
Industry
Phone
(302) 252-9160
Address
2711 CENTERVILLE ROAD, WILMINGTON
Compare ENOV vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
24.12 | 1.34B | 2.25B | -1.18B | 19.92M | -20.69 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Resumed | William Blair | Outperform |
| Jan-06-26 | Initiated | BTIG Research | Buy |
| Oct-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Jun-13-24 | Initiated | JP Morgan | Neutral |
| Feb-13-24 | Initiated | Stephens | Overweight |
| Jan-22-24 | Initiated | UBS | Buy |
| Jan-03-24 | Initiated | William Blair | Outperform |
| Dec-15-23 | Reiterated | Needham | Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Jun-26-23 | Initiated | Needham | Buy |
| May-12-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-11-22 | Initiated | Goldman | Buy |
| Sep-12-22 | Initiated | Canaccord Genuity | Buy |
| Sep-12-22 | Initiated | Evercore ISI | Outperform |
| Jun-28-22 | Initiated | Argus | Hold |
| Jun-27-22 | Resumed | Loop Capital | Buy |
| Jun-16-22 | Initiated | Wells Fargo | Equal Weight |
View All
Enovis Corp Stock (ENOV) Latest News
Did William Blair’s FCF-Focused ENOV Call Just Shift Enovis’ Investment Narrative? - Yahoo Finance
MSN Money - MSN
William Blair’s Focus on Cash Conversion Might Change The Case For Investing In Enovis (ENOV) - simplywall.st
Enovis (NYSE:ENOV) Downgraded by Wall Street Zen to "Hold" - MarketBeat
William Blair Initiates Enovis Corporation Coverage with Outperform Rating - HarianBasis.co
Enovis (ENOV) earnings expected to grow: What to know ahead of next week's release - MSN
William Blair Assigns Outperform Rating to Enovis (ENOV) - Insider Monkey
Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Enovis (ENOV) to Release Earnings on Thursday - MarketBeat
Vanguard reports 5.23% stake in Enovis | ENOV SEC FilingForm SCHEDULE 13G - Stock Titan
LK Balanced Fund's Enovis Corp(ENOV) Holding History - GuruFocus
Vanguard Portfolio Management boosts stake in Enovis (ENOV) to 3.91M shares - Stock Titan
3 Reasons to Sell ENOV and 1 Stock to Buy Instead - The Globe and Mail
Is Enovis Corp (ENOV) a Bargain After 4.7% Drop? GF Value Says U - GuruFocus
Despite fast-paced momentum, Enovis (ENOV) is still a bargain stock - msn.com
Enovis (ENOV) 2024 Wells Fargo Healthcare Conference Summary - Quartr
Enovis Corporation $ENOV Shares Acquired by Impax Asset Management Group plc - MarketBeat
Canaccord Genuity Sticks to Its Buy Rating for Enovis (ENOV) - The Globe and Mail
Enovis (ENOV) 2026 CG Musculoskeletal Conference Summary - Quartr
CCORF Initiates Enovis Corp(ENOV.US) With Buy Rating, Announces Target Price $50 - Moomoo
ENOV (Enovis Corporation) shares rise 4.4 percent after 2025 fourth quarter EPS tops analyst estimates by 13 percent.Trending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai
Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock - Yahoo Finance
Enovis (NYSE:ENOV) Trading Down 7.7%Here's Why - MarketBeat
William Blair Initiates Enovis Corp(ENOV.US) With Buy Rating - 富途牛牛
What could move Enovis Corporation (ENOV) stock later today (+0.27%) 2026-04-20Trending Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Analyst backs Enovis on cash flow turnaround - MSN
Tributary Capital Management LLC Trims Stake in Enovis Corporation $ENOV - MarketBeat
Deroy & Devereaux Private Investment Counsel Inc. Acquires New Shares in Enovis Corporation $ENOV - MarketBeat
Does The Recent Rebound In Enovis (ENOV) Share Price Reflect Its True Worth? - Yahoo Finance
ENOV Assumed by William Blair -- Rating Maintained as Outperform - GuruFocus
Analyst Backs Enovis On Cash Flow Turnaround - Benzinga
Enovis Coverage Assumed by William Blair at Outperform - Moomoo
Enovis' (ENOV) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
William Blair assumes Enovis stock coverage with outperform rating By Investing.com - Investing.com Australia
William Blair assumes Enovis stock coverage with outperform rating - Investing.com
Enovis assumed with an Outperform at William Blair - TipRanks
Enovis: Discounted Valuation With Clear Free Cash Flow Upside and Product Catalysts Support Buy Rating - TipRanks
Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Is It Time To Reconsider Enovis (ENOV) After Recent Share Price Rebound - simplywall.st
Maplebear to Join S&P MidCap 400 as Enovis Moves to S&P SmallCap 600 in January 2025 - geneonline.com
S&P reshuffle puts Maplebear in MidCap 400, moves Enovis to 600 - Stock Titan
Enovis : Proxy Statement 2026 - marketscreener.com
BTIG Sticks to Its Buy Rating for Enovis (ENOV) - The Globe and Mail
Enovis price target lowered to $39 from $43 at BTIG - TipRanks
BTIG Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $39 - 富途牛牛
Enovis to Host First Quarter 2026 Results Conference Call on May 7th - marketscreener.com
A Look At Enovis (ENOV) Valuation After Recent Share Price Rebound From A Weaker Year - simplywall.st
Enovis Corp Stock (ENOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):